ProPhase Labs, Inc. (PRPH) News
Filter PRPH News Items
PRPH News Results
|Loading, please wait...|
Latest PRPH News From Around the Web
Below are the latest news stories about ProPhase Labs Inc that investors may wish to consider to help them evaluate PRPH as an investment opportunity.
ProPhase Labs (NASDAQ:PRPH) declares $0.30/share special dividend.Payable March 10; for shareholders of record March 1; ex-div Feb.
Anticipates Record Q4 2021 and Q1 2022 Revenues and Profits Garden City, NY, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, announced today that its Board of Directors has declared a special cash dividend in the amount of $0.30 per share on its common stock, payable on March 10, 2022 to stockholders of record as of March 1, 2022. “Given our strong projected financial performance in net income and EBITDA for the fourth quarter of
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
GARDEN CITY, NY, Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the MicroCap Rodeo Winter Wonderland Best Ideas Conference, which is being held virtually from February 8 – 11, 2022. Mr. Karkus will deliver his corporate presentation on Wednesday, February 9, 2022 at 12:00 PM ET. Event Webcast URL: https://www.webcaster4.com/Webcast/Page/2840/44555 Mr. Karkus will be
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th \- 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The virtual conference begins on Tuesday, February 8th, 2022, with company presentations beginning at 8:30 am Eastern Time.
ProPhase Labs (PRPH) announces that testing volumes exceeded well over 300,000 PCR COVID-19 tests during Q4 2021
Q1 2022 Testing Volumes will Significantly Exceed Previous Record Results from Q1 2021 Significant year-over-year growth expected for the next four quarters Garden City, NY, Jan. 13, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, today announces that testing volumes exceeded well over 300,000 PCR COVID-19 tests during Q4 2021. These record results are significantly greater than the Company’s previous record levels of approximately 110,000
GARDEN CITY, NY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022. The presentation will be available on-demand beginning at 7:00 a.m. ET on Monday, January 10, 2022, to H.C. Wainwright registered attendees of the conference. Register for the con
Investment analysts at HC Wainwright began coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a report issued on Monday, Price Targets.com reports. The brokerage set a buy rating and a $12.00 price target on the stock. HC Wainwrights target price indicates a potential upside of 52.09% from the stocks current price. A number of other 
ProPhase Labs Continues to Build Strong Leadership with Key Promotions and Additions to Management Team
Precision Medicine division adds Industry Veteran Sam A. Beeler as Chief Strategy Officer; Diagnostics Division Promotes Alice Lioi and Jason Karkus to EVP and Co-Chief Operating Officers and Sergio Miralles to EVP/ Chief Information Officer